-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Addressing Current Questions and Controversies in the Management of Myelofibrosis - What Clinicians Want to Know

Sponsor: educational grants from CTI BioPharma, a Sobi Company, Geron Corporation, GSK, Incyte Corporation and Karyopharm Therapeutics
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Education, Diseases
Friday, December 6, 2024: 11:00 AM-2:00 PM
Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)
Chair:
Andrew T. Kuykendall, MD, H. Lee Moffitt Cancer Center and Research Institute
Disclosures:
Kuykendall: Incyte: Honoraria; PharmaEssentia: Honoraria; Novartis: Research Funding; Protagonist Therapeutics: Honoraria, Research Funding.
Speakers:
Abdulraheem Yacoub, MD, University of Kansas Cancer Center , Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center and Angela G. Fleischman, MD, PhD, University of California, Irvine
Disclosures:
Yacoub: Servier: Consultancy; AbbVie: Consultancy; Karyopharm Therapeutics INC: Consultancy; Novartis: Consultancy; Pfizer: Consultancy; Pharmaessentia: Consultancy; CTI Pharma (SOBI), Stemline Therapuitics: Research Funding; GSK: Consultancy; Blueprint Medicine: Consultancy; Apellis: Consultancy; Gilead: Consultancy; Notable Labs: Consultancy; Protagonist: Consultancy; Incyte, CTI Pharma (SOBI), Pharmaessentia, Pfizer (Feb 22), Novartis, Servier, ABBVIE, Karyopharm Therapeutics INC , GSK, Blueprint Medicine, Apellis, Gilead, Notable Labs, Protagonist: Consultancy; CTI Pharma: Consultancy. Bose: Kartos: Honoraria, Research Funding; Blueprint: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Cogent: Honoraria, Research Funding; CTI Biopharma Corp: Honoraria, Research Funding; GSK: Honoraria; Disc Medicine: Research Funding; Incyte: Honoraria, Research Funding; Ionis Pharmaceuticals: Research Funding; AbbVie: Honoraria; Karyopharm: Honoraria; MorphSys: Honoraria, Research Funding; Novartis: Honoraria; PharmaEssentia: Honoraria; Telios: Research Funding; Astellas: Research Funding; Pfizer: Research Funding; NS Pharma: Research Funding; Promedior: Research Funding.

This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with myelofibrosis. Four clinical investigators will serve as faculty for the program, one of whom will moderate. To create a relevant agenda, prior to the symposium Research To Practice (RTP) will recruit 50 general medical oncologists/hematologists to complete a survey designed to evaluate their educational interests and knowledge deficiencies related to the treatment of myelofibrosis. During the symposium, selected results from the survey highlighting areas of greatest interest will be presented. The faculty members will then review relevant research findings, discuss evidence-based treatment approaches and provide perspectives on ongoing studies. Actual questions contributed by the survey respondents as well as audience members will be integrated into the proceedings. The live activity will be recorded and developed into an enduring CME resource and promoted by RTP to 46,500 subscribers worldwide.